This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cell Therapeutics' Deal Begs $18 Million Questions

After Monday's close, Cell Therapeutics (CTIC - Get Report) said it was selling 2.59 million shares of common stock to several unnamed institutional investors in a registered direct offering at $7.10. The offering, raising about $18 million, is priced at a 19% discount to Cell Therapeutics' Monday closing price of $8.46.

Tuesday, the company also said it has inked a $30 million financing agreement for its marketed drug Trisenox.

The timing of this stock sale is very peculiar and worrisome if you're a Cell Therapeutics fan. For the past six months or so, CEO Jim Bianco has been telling anyone who will listen about how well the company's lung cancer drug Xyotax seems to be performing in an ongoing phase III clinical trial. While always careful to say that data from the so-called Stellar 3 study are still blinded to the company, Bianco has repeatedly pushed back timelines for the completion of the study because enrolled patients are living longer than expected. Last week, Bianco said to expect results from Stellar 3 at the end of the first quarter 2005, delayed from earlier in the quarter.

Are these patients living longer because of Xyotax? Bianco claims not to know yet (the longer-than-expected survival represents a blended group of patients taking the drug or a placebo). But then again, Bianco loves to spout historical statistics about how similar lung cancer patients in other studies rarely live this long. These historical comparisons (with a nudge, nudge and a wink, wink) are supposed to make you believe that Xyotax is working, that Stellar 3 study will be a success, and that Xyotax is destined for regulatory approval.

Such public posturing by a company conducting an ongoing pivotal study is promotional and highly unusual, even questionable. You don't see executives from Genentech (DNA) or Biogen Idec (BIIB) providing running commentary on how many patients have died in their ongoing clinical studies. I'm half expecting Cell Therapeutics to stick a patient death "counter" on its Web site!

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
CTIC $1.84 0.00%
AAPL $128.70 0.00%
FB $78.81 0.00%
GOOG $540.78 0.00%
TSLA $230.51 0.00%

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs